Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: A pooled study of baseline EORTC QLQ-C30 data

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 5, 2011, Pages 587-599

  Martinelli, Francesca ^a   Quinten, Chantal ^a   Maringwa, John T ^a   Coens, Corneel ^a   Vercauteren, Jurgen ^a,b   Cleeland, Charles S ^c   Flechtner, Henning ^d   Gotay, Carolyn ^e   Greimel, Eva ^f   King, Madeleine ^g   Mendoza, Tito ^c   Osoba, David ^h   Reeve, Bryce B ⁱ   Ringash, Jolie ^j   Koch, Joseph Schmucker Von ^k   Shi, Qiuling ^c   Taphoorn, Martin J ^l   Weis, Joachim ^m   Bottomley, Andrew ^a  

^a EORTC DATA CENTER   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Clinic for Child and Adolescent Psychiatry and Psychotherapy   (Germany)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF GRAZ   (Austria)

^g UNIVERSITY OF SYDNEY   (Australia)

^h Quality of Life Consulting   (Canada)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

^k UNIVERSITY OF REGENSBURG   (Germany)

^l VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^m UNIVERSITY OF FREIBURG   (Germany)

more..

Author keywords

cancer; clinical trials; cluster analysis; patient reported outcomes; quality of life

Indexed keywords

ADULT; ANOREXIA; ARTICLE; CANCER PATIENT; CLINICAL TRIAL (TOPIC); CLUSTER ANALYSIS; COGNITIVE DEFECT; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DYSPNEA; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE CORE QUESTIONNAIRE 30; FATIGUE; FEMALE; FUNCTIONAL STATUS; HEALTH STATUS; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; QUALITY OF LIFE; QUESTIONNAIRE;

ADULT; AGED; CLINICAL TRIALS AS TOPIC; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 80053535111     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.51     Document Type: Article

References (56)

1. Winer E, Gralow J, Diller L et al. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J. Clin. Oncol. 27(5), 812-826 (2009).
2. Blank PR, Dedes KJ, Szucs TD. Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review. Pharmacoeconomics 28(8), 629-647 (2010).
3. Garcia SF, Cella D, Clauser SB et al. Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J. Clin. Oncol. 25(32), 5106-5112 (2007). (Pubitemid 350232291)
4. Pisanu A, Montisci A, Piu S, Uccheddu A. Curative surgery for gastric cancer in the elderly: treatment decisions, surgical morbidity, mortality, prognosis and quality of life. Tumori 93(5), 478-484 (2007). (Pubitemid 350203922)
5. Svensson H, Hatschek T, Johansson H, Einbeigi Z, Brandberg Y. Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer. Med. Oncol. DOI: 10.1007/s12032-011-9844-9 (2011) (Epub ahead of print).
6. Quinten C, Coens C, Mauer M et al.; EORTC Clinical Groups. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 10(9), 865-871 (2009).
7. Cella D, Riley W, Stone A et al.; PROMIS Cooperative Group. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J. Clin. Epidemiol. 63(11), 1179-1194 (2010).
8. Chen ML, Tseng HC. Symptom clusters in cancer patients. Support. Care Cancer 14(8), 825-830 (2006).
9. Dodd MJ, Miaskowski C, Lee KA. Occurrence of symptom clusters. J. Natl Cancer Inst. Monogr. 32, 76-78 (2004).
10. Miaskowski C, Dodd M, Lee K. Symptom clusters: the new frontier in symptom management research. J. Natl Cancer Inst. Monogr. 32, 17-21 (2004).
11. Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol. Nurs. Forum 28(3), 465-470 (2001).
12. Kim HJ, McGuire DB, Tulman L, Barsevick AM. Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs. 28(4), 270-282 (2005).
13. Cheung WY, Le LW, Zimmermann C Symptom clusters in patients with advanced cancers. Support. Care Cancer 17(9), 1223-1230 (2009).
14. Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support. Care Cancer 8(3), 175-179 (2000). (Pubitemid 30183032)
15. Maliski SL, Kwan L, Elashoff D, Litwin MS. Symptom clusters related to treatment for prostate cancer. Oncol. Nurs. Forum 35(5), 786-793 (2008).
16. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85(5), 365-376 (1993). (Pubitemid 23073154)
17. Bottomley A, Aaronson NK. International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience. J. Clin. Oncol. 25(32), 5082-5086 (2007). (Pubitemid 350232287)
18. Bottomley A, Flechtner H, Efficace F et al. Health related quality of life outcomes in cancer clinical trials. Eur. J. Cancer 41(12), 1697-1709 (2005). (Pubitemid 41135868)
19. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A; on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). European Organisation for Research and Treatment of Cancer, Brussels, Belgium (2001).
20. Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual. Life Res. 3(5), 353-364 (1994). (Pubitemid 24358751)
21. Basch E, Jia X, Heller G et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J. Natl Cancer Inst. 101(23), 1624-1632 (2009).
22. Khattree R, Naik D. Cluster analysis. In: Multivariate Data Reduction and Discrimination with SAS Software. John Wiley & Sons Inc., NY, USA, 367-380 (2000).
23. Ward J. Hierarchical grouping to optimize an objective function. J. Am. Stat. Assoc. 58, 236-244 (1963).
24. Cronbach LJ. Coefficient a and the internal structure of tests. Psychometrika 16, 297-334 (1951).
25. Ataman F, Poortmans P, Stupp R, Fisher B, Mirimanoff RO. Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. Eur. J. Cancer 40(11), 1724-1730 (2004). (Pubitemid 38902908)
26. van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III trial. J. Clin. Oncol. 24(18), 2715-2722 (2006). (Pubitemid 46630567)
27. Efficace F, Therasse P, Piccart MJ et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J. Clin. Oncol. 22(16), 3381-3388 (2004). (Pubitemid 41103697)
28. Pajk B, Cufer T, Canney P et al. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline-and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized Phase II trial. Breast 17(2), 180-185 (2008). (Pubitemid 351467955)
29. Keilholz U, Punt CJ, Gore M et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized Phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J. Clin. Oncol. 23(27), 6747-6755 (2005). (Pubitemid 46190270)
30. Eggermont AM, Suciu S, Santinami M et al.; EORTC Melanoma Group Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised Phase III trial. Lancet 372(9633), 117-126 (2008). (Pubitemid 351952257)
31. Eggermont AM, Suciu S, MacKie R et al.; EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366(9492), 1189-1196 (2005). (Pubitemid 41393597)
32. Bernier J, Domenge C, Ozsahin M et al.; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 350(19), 1945-1952 (2004). (Pubitemid 38580197)
33. Lefebvre JL, Rolland F, Tesselaar M et al.; EORTC Head and Neck Cancer Cooperative Group; EORTC Radiation Oncology Group. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J. Natl Cancer Inst. 101(3), 142-152 (2009).
34. van Meerbeeck JP, Gaafar R, Manegold C et al.; European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 23(28), 6881-6889 (2005).
35. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C et al.; European Organization for Research and Treatment of Cancer Lung Cancer Group. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a Phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J. Clin. Oncol. 21(21), 3909-3917 (2003). (Pubitemid 46606203)
36. Kramer GW, Legrand CL, van Schil P et al.; EORTC-Lung Cancer Group. Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy. Eur. J. Cancer 2(10), 1391-1398 (2006). (Pubitemid 43903157)
37. Belderbos J, Uitterhoeve L, van Zandwijk N et al.; EORTC LCG and RT Group. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur. J. Cancer 43(1), 114-121 (2007). (Pubitemid 46054477)
38. Bottomley A, Debruyne C, Felip E et al. Symptom and quality of life results of an international randomised Phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur. J. Cancer 44(15), 2178-2184 (2008).
39. Köhne CH, Wils J, Lorenz M, Schöffski P et al.; European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. Randomized Phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J. Clin. Oncol. 21(20), 3721-3728 (2003). (Pubitemid 46606225)
40. Giacchetti S, Bjarnason G, Garufi C; European Organisation for Research and Treatment of Cancer Chronotherapy Group. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J. Clin. Oncol. 24(22), 3562-3569 (2006). (Pubitemid 46630527)
41. Köhne CH, van Cutsem E, Wils J; European Organisation for Research and Treatment of Cancer Gastrointestinal Group. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J. Clin. Oncol. 23(22), 4856-4865 (2005). (Pubitemid 46223990)
42. Conroy T, Etienne PL, Adenis A et al.; European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann. Oncol. 13(5), 721-729 (2002). (Pubitemid 34567378)
43. Fosså SD, Curran D, Aaronson NK et al. Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase III trial 30893. Eur. Urol. 37(5), 541-551 (2000). (Pubitemid 30189822)
44. Oosterhof GO, Roberts JT, de Reijke TM et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a Phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur. Urol. 44(5), 519-526 (2003). (Pubitemid 37328625)
45. Albrecht W, Van Poppel H, Horenblas S et al. Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. Br. J. Cancer 90(1), 100-105 (2004). (Pubitemid 38174946)
46. Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J. Clin. Oncol. 22(12), 2461-2468 (2004). (Pubitemid 41115405)
47. de Wit R, Roberts JT, Wilkinson PM et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3-or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J. Clin. Oncol. 19(6), 1629-1640 (2001). (Pubitemid 32230862)
48. McLachlan SA, Devins GM, Goodwin PJ. Factor analysis of the psychosocial items of the EORTC QLQ-C30 in metastatic breast cancer patients participating in a psychosocial intervention study. Qual. Life Res. 8(4), 311-317 (1999). (Pubitemid 29369635)
49. Gotay CC, Blaine D, Haynes SN, Holup J, Pagano IS. Assessment of quality of life in a multicultural cancer patient population. Psychol. Assess. 14(4), 439-450 (2002). (Pubitemid 35440488)
50. Cleeland CS, Bennett GJ, Dantzer R et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 97(11), 2919-2925 (2003). (Pubitemid 36605163)
51. Fan G, Filipczak L, Chow E. Symptom clusters in cancer patients: a review of the literature. Curr. Oncol. 14(5), 173-179 (2007).
52. Bernhard J, Cella DF, Coates AS. Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat. Med. 17(5-7), 517-532 (1998). (Pubitemid 28118924)
53. Yuasa H, Kurita K, Westesson PL. External validity of a randomised clinical trial of temporomandibular disorders: analysis of the patients who refused to participate in research. Br. J. Oral Maxillofac. Surg. 41(2), 129-131 (2003). (Pubitemid 36546795)
54. Parker PA, Pettaway CA, Babaian RJ et al. The effects of a presurgical stress management intervention for men with prostate cancer undergoing radical prostatectomy. J. Clin. Oncol. 27(19), 3169-3176 (2009).
55. World Health Organisation www.who.int
56. National Cancer Institute: Surveillance Epidemology and End Results www.seer.cancer.gov